+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Tumor Necrosis Factor Receptor Superfamily Member 10A - Pipeline Review, H2 2019

  • ID: 4900106
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 51 pages
  • Global Markets Direct

FEATURED COMPANIES

  • AbbVie Inc
  • Clover Biopharmaceuticals
  • Galaxy Biotech LLC
  • i2 Pharmaceuticals Inc
  • JN Biosciences LLC
  • MORE
Tumor Necrosis Factor Receptor Superfamily Member 10A - Pipeline Review, H2 2019

Summary

Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A) or Death receptor 4 (DR4) is a protein encoded by TNFRSF10A. This receptor is activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL), and thus transduces cell death signal and induces cell apoptosis. It promotes the activation of NF-kappa-B.

Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) pipeline Target constitutes close to 13 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 2, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Hematological Disorders and Respiratory which include indications Colorectal Cancer, Solid Tumor, Colon Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Blood Cancer, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Gastrointestinal Tract Cancer, Malignant Ascites, Malignant Pleural Effusion, Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Peritoneal Cancer, Refractory Multiple Myeloma and Relapsed Multiple Myeloma.

The latest report Tumor Necrosis Factor Receptor Superfamily Member 10A - Pipeline Review, H2 2019, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A)
  • The report reviews Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc
  • Clover Biopharmaceuticals
  • Galaxy Biotech LLC
  • i2 Pharmaceuticals Inc
  • JN Biosciences LLC
  • MORE
Introduction
Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Companies Involved in Therapeutics Development
AbbVie Inc
Beijing Sunbio Biotech Co Ltd
Chengdu Huachuang Biotechnology Co Ltd
Clover Biopharmaceuticals
Galaxy Biotech LLC
i2 Pharmaceuticals Inc
JN Biosciences LLC
Polaris Pharmaceuticals Inc
Shanghai Gebaide Biotechnology Co Ltd
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Drug Profiles
ABBV-621 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CD19L-sTRAIL - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dulanermin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Agonize TRAIL Receptor 1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HuD-114 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HuYON-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-921 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
POL-30000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize TNFRSF10A, TNFRSF10B, TNFRSF10C and TNFRSF10D for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCB-313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-231 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize DR4 and DR5 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Dormant Products
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Discontinued Products
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Product Development Milestones
Featured News & Press Releases
Nov 21, 2019: Clover Biopharmaceuticals doses first patient in Phase I study of SCB-313 in Australia for Malignant Pleural Effusions (MPE)
Sep 29, 2019: Clover Biopharmaceuticals doses first patient in phase I study of SCB-313 in China for Malignant Ascites
Sep 10, 2019: Clover Biopharmaceuticals doses first patient in phase I study of SCB-313 in China for Peritoneal Carcinomatosis
May 30, 2019: AbbVie presents update on ABBV-621 at the 2019 ASCO
May 07, 2019: Clover Biopharmaceuticals receives NMPA approval for SCB-313 (TRAIL-Trimer) to initiate clinical trials in China
Jun 18, 2018: Clover Biopharmaceuticals Doses First Patient in Australia in Phase I Study of SCB-313 for Malignant Ascites
Nov 21, 2017: AbbVie to Present Data on Cancer Drug Candidate ABBV-621 at the 2017 American Society of Hematology Annual Meeting & Exposition
Apr 11, 2017: Apogenix Announces Initiation of Clinical Development for ABBV-621 to Treat Solid and Hematologic Tumors by Partner AbbVie
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbbVie Inc, H2 2019
Pipeline by Beijing Sunbio Biotech Co Ltd, H2 2019
Pipeline by Chengdu Huachuang Biotechnology Co Ltd, H2 2019
Pipeline by Clover Biopharmaceuticals, H2 2019
Pipeline by Galaxy Biotech LLC, H2 2019
Pipeline by i2 Pharmaceuticals Inc, H2 2019
Pipeline by JN Biosciences LLC, H2 2019
Pipeline by Polaris Pharmaceuticals Inc, H2 2019
Pipeline by Shanghai Gebaide Biotechnology Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
  • AbbVie Inc
  • Beijing Sunbio Biotech Co Ltd
  • Chengdu Huachuang Biotechnology Co Ltd
  • Clover Biopharmaceuticals
  • Galaxy Biotech LLC
  • i2 Pharmaceuticals Inc
  • JN Biosciences LLC
  • Polaris Pharmaceuticals Inc
  • Shanghai Gebaide Biotechnology Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll